BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Drug discovery for TB: Targeting energy metabolism with TMC207
DTSTART:20110318T140000
DTSTAMP:20260920T164824Z
UID:ca3431b38e2ae45dbf13cd623745525b0df61854919f414fe648cd1a
CATEGORIES:Conferences - Seminars
DESCRIPTION:Dr. Anil Koul\, Department of Antimicrobial Research\, Johnson
  and Johnson\, Belgium\nTuberculosis kills more people today than any othe
 r time in human history. TMC207 is currently in late stage clinical develo
 pment for treatment of multi-drug resistant (MDR) tuberculosis. This prese
 ntation will give you an overall update on TMC207 and address some of the 
 key questions on how to identify and discover new TB drugs.
LOCATION:AI 1153 https://plan.epfl.ch/?room==AI%201153
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR